as 06-06-2025 2:30pm EST
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 15.5M | IPO Year: | N/A |
| Target Price: | $4.00 | AVG Volume (30 days): | 28.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.15 - $11.19 | Next Earning Date: | 05-15-2025 |
| Revenue: | $183,000 | Revenue Growth: | 88.66% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
ABP Breaking Stock News: Dive into ABP Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
GlobeNewswire
2 months ago
GlobeNewswire
3 months ago
GlobeNewswire
6 months ago
The information presented on this page, "ABP Abpro Holdings Inc Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.